| Not Yet Recruiting | Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-r NCT06681363 | Nantes University Hospital | — |
| Not Yet Recruiting | Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT NCT07254793 | University of Arizona | Phase 1 |
| Recruiting | Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT NCT06551584 | Stanford University | Phase 1 |
| Recruiting | Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leu NCT06427330 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia NCT05827549 | Ho Joon Im | Phase 2 |
| Recruiting | UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 NCT05535855 | University of Colorado, Denver | Phase 1 |
| Recruiting | Study of the Medullary Microenvironment in Acute Childhood Leukemia NCT05792007 | University Hospital, Tours | N/A |
| Active Not Recruiting | Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant NCT04167683 | Rigshospitalet, Denmark | — |
| Active Not Recruiting | Muscle Dysfunction in Patients With Haematological Diseases NCT05150561 | Rigshospitalet, Denmark | — |
| Recruiting | Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil NCT05959720 | Instituto do Cancer do Estado de São Paulo | — |
| Unknown | H19 in Acute Lymphoblastic Leukemia. NCT05943093 | Assiut University | — |
| Recruiting | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or R NCT05442515 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Suspended | Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) NCT05322850 | University of Florida | Phase 1 / Phase 2 |
| Active Not Recruiting | Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic NCT05316701 | Orca Biosystems, Inc. | Phase 3 |
| Completed | Latin American Real-world Study in Acute Leukemia NCT05166135 | Pfizer | — |
| Active Not Recruiting | Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractor NCT04778579 | Sara V. Latorre | Phase 2 |
| Completed | PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT NCT04669210 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Withdrawn | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation NCT04464889 | Medigene AG | Phase 1 |
| Active Not Recruiting | Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancie NCT04013685 | Orca Biosystems, Inc. | Phase 1 |
| Unknown | Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia NCT03610438 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Completed | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001 NCT03833180 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Completed | Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia NCT03367299 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Completed | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD NCT03448393 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tum NCT02933333 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 |
| Completed | Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery NCT02767388 | University of Nebraska | — |
| Unknown | The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Reg NCT02413021 | Isfahan University of Medical Sciences | Phase 1 |
| Completed | The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents NCT02953730 | Chinese Academy of Medical Sciences | Phase 4 |
| Terminated | iCare for Cancer Patients NCT02435550 | University of Florida | N/A |
| Completed | Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplan NCT02458235 | University of California, San Francisco | Phase 2 |
| Terminated | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignanc NCT02419755 | St. Jude Children's Research Hospital | Phase 2 |
| Unknown | Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia NCT02345915 | Institut Paoli-Calmettes | N/A |
| Completed | Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT NCT02294552 | Ivan S Moiseev | Phase 2 |
| Unknown | Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT NCT03977103 | University Of Perugia | Phase 2 |
| Unknown | Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete NCT02605460 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 2 |
| Terminated | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylax NCT01749111 | Hospital Israelita Albert Einstein | Phase 3 |
| Completed | Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant NCT01720264 | Sherif S. Farag | Phase 2 |
| Completed | Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies NCT01461538 | Seagen Inc. | Phase 2 |
| Completed | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies NCT01344876 | Otsuka Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) NCT01037764 | Asan Medical Center | Phase 2 |
| Completed | Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia ( NCT00983138 | medac GmbH | Phase 2 |
| Temporarily Not Available | Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies NCT07346105 | Orca Biosystems, Inc. | — |
| No Longer Available | Erwinase Master Treatment Protocol NCT00590915 | Phoenix Children's Hospital | — |